New 3 year data supports Kite ‘cure’ hopes for CAR-T – pharmaphorum
pharmaphorum |
New 3 year data supports Kite 'cure' hopes for CAR–T
pharmaphorum The study involved Kite's own CAR–T candidate KTE019, which will soon be reviewed by the FDA in in patients with aggressive NHL including diffuse large B-cell lymphoma (DLBCL). Kite is chasing Novartis, which just two weeks ago received a landmark … |
